Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic acid in patients with moderate to severe chronic heart failure and osteoporosis
ChiCTR2100042910Phase 4Recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of zoledronic acid in osteoporosis and chronic heart failure (CHF) (2 arms), sponsored by Nanjing Drum-Tower Hospital. Primary endpoints: New York Heart Association classification, Bone mineral density and 6 more. Started Jan 2021; status: recruiting.
02
Drugs
zoledronic acid
03
Conditions
osteoporosischronic heart failure (CHF)
Beyond the preview
Go deeper on ChiCTR2100042910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100042910.